🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT07288333
Recruiting Phase 2

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

NCT07288333 · tracked via the Priya Life Science UK tracker
Sponsor
Neurocrine Biosciences
Phase
Phase 2
Started
2026-02-16
Last updated
2026-07-22

Condition(s) studied

Schizophrenia

Investigational drug(s) / intervention(s)

NBI-1117570Placebo

NBI-1117570: Oral administration

Placebo: Oral administration

Study summary

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Key Inclusion Criteria: * 18 to 55 years of age * Primary diagnosis of schizophrenia ≥1 year before screening. * Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization. * Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the treatment of a prior acute relapse. Key Exclusion Criteria: * Considered to be at imminent risk of suicide or injury to self or others. * History of epilepsy, seizures, or convulsions. * Has orthostatic hypotension, or history of pulmonary hypertension, obstructive coronary artery disease, hypertrophic cardiomyopathy, myocardial infarction, coronary artery revascularization, heart failure, left ventricular hypertrophy, moderate or severe cardiac valvopathy, or other cardiovascular conditions or measures that would preclude participation. * Currently taking prohibited medications. * Pregnant or lactating. Note: Additional inclusion/exclusion criteria may apply, per protocol.

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Neurocrine Clinical Site Kazanlak Bulgaria Recruiting
Neurocrine Clinical Site Pazardzhik Bulgaria Recruiting
Neurocrine Clinical Site Targovishte Bulgaria Recruiting
Neurocrine Clinical Site Târgu Mureş Romania Recruiting
Neurocrine Clinical Site London United Kingdom Recruiting
Neurocrine Clinical Site Oxford United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07288333 on ClinicalTrials.gov ↗ ← All trials in the UK